Prescription Drugs: Global Strategic Business Report

Report
150 Pages
April 2024
Region: Global
Global Industry Analysts, Inc
ID: 5662749

Global Prescription Drugs Market to Reach $3 Trillion by 2030

The global market for Prescription Drugs estimated at US$1.9 Trillion in the year 2022, is projected to reach a revised size of US$3 Trillion by 2030, growing at a CAGR of 5.9% over the analysis period 2022-2030. Generics, one of the segments analyzed in the report, is projected to record a 5.8% CAGR and reach US$498 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Orphan Drugs segment is readjusted to a revised 6.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $523.4 Billion, While China is Forecast to Grow at 9.5% CAGR

The Prescription Drugs market in the U.S. is estimated at US$523.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$668.3 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$416.2 Billion by the year 2030.

Select Competitors (Total 23 Featured) -

AbbVie, Inc.
Allergan PLC
Amgen, Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co., Inc.
Novartis International AG
Novo Nordisk A/S
Pfizer, Inc.
Sanofi
Shire PLC
Teva Pharmaceutical Industries Ltd.

What's New?

Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
Global competitiveness and key competitor percentage market shares
Market presence across multiple geographies - Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and Research Platform
Complimentary updates for one year

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Prescription Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 5: World Historic Review for Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 6: World 16-Year Perspective for Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 8: World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 9: World 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 11: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 14: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 15: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for Anti-Diabetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 17: World Historic Review for Anti-Diabetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Anti-Diabetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for Sensory Organs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 20: World Historic Review for Sensory Organs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 21: World 16-Year Perspective for Sensory Organs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 23: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 24: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 26: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 27: World 16-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 28: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 29: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 30: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
Table 31: World Prescription Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
Table 32: USA Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 33: USA Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 34: USA 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 35: USA Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 36: USA Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 37: USA 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

CANADA

Table 38: Canada Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 39: Canada Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 40: Canada 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 41: Canada Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 42: Canada Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 43: Canada 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

JAPAN

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 44: Japan Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 45: Japan Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 46: Japan 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 47: Japan Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 48: Japan Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 49: Japan 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

CHINA

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 51: China Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 52: China 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 53: China Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 54: China Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 55: China 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

EUROPE

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 56: Europe Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 57: Europe Historic Review for Prescription Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 58: Europe 16-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
Table 59: Europe Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 60: Europe Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 61: Europe 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 62: Europe Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 63: Europe Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 64: Europe 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

FRANCE

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 65: France Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 66: France Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 67: France 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 68: France Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 69: France Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 70: France 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

GERMANY

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 71: Germany Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 72: Germany Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 73: Germany 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 74: Germany Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 75: Germany Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 76: Germany 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

ITALY

Table 77: Italy Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 78: Italy Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 79: Italy 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 80: Italy Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 81: Italy Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 82: Italy 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

UNITED KINGDOM

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 83: UK Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 84: UK Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 85: UK 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 86: UK Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 87: UK Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 88: UK 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

SPAIN

Table 89: Spain Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 90: Spain Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 91: Spain 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 92: Spain Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 93: Spain Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 94: Spain 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

RUSSIA

Table 95: Russia Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 96: Russia Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 97: Russia 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 98: Russia Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 99: Russia Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 100: Russia 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

REST OF EUROPE

Table 101: Rest of Europe Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 102: Rest of Europe Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 103: Rest of Europe 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 104: Rest of Europe Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 105: Rest of Europe Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 106: Rest of Europe 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

ASIA-PACIFIC

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Table 108: Asia-Pacific Historic Review for Prescription Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 109: Asia-Pacific 16-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 111: Asia-Pacific Historic Review for Prescription Drugs by Type - Generics, Orphan Drugs and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 112: Asia-Pacific 16-Year Perspective for Prescription Drugs by Type - Percentage Breakdown of Value Sales for Generics, Orphan Drugs and Other Types for the Years 2014, 2023 & 2030
Table 113: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Table 114: Asia-Pacific Historic Review for Prescription Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
Table 115: Asia-Pacific 16-Year Perspective for Prescription Drugs by Therapy - Percentage Breakdown of Value Sales for Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants, Anticoagulants and Other Therapies for the Years 2014, 2023 & 2030

AUSTRALIA

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)

INDIA

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

Prescription Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie, Inc.
Allergan PLC
Amgen, Inc.
AstraZeneca PLC
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co., Inc.
Novartis International AG
Novo Nordisk A/S
Pfizer, Inc.
Sanofi
Shire PLC
Teva Pharmaceutical Industries Ltd.

Table Information

Report Attribute	Details
No. of Pages	150
Published	April 2024
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 1.9 Trillion
Forecasted Market Value ( USD ) by 2030	$ 3 Trillion
Compound Annual Growth Rate	5.9%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5439EUR$5,600USD£4,692GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10334EUR$10,640USD£8,915GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16317EUR$16,800USD£14,076GBP

Global Prescription Drugs Market to Reach $3 Trillion by 2030

The U.S. Market is Estimated at $523.4 Billion, While China is Forecast to Grow at 9.5% CAGR

Select Competitors (Total 23 Featured) -

What's New?

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Omega 3 Prescription Drugs Global Market Report 2024

Global Pharma B2B eCommerce Market by Business Model (B2B2B, B2B2C), Product Type (Over-the-Counter (OTC) Products, Prescription Drugs), Therapeutic Area, Distribution Type - Forecast 2024-2030

Global Vitamin D Therapy Market by Route of Administration (Oral Route of Administration, Parenteral Route of Administration), Purchasing Pattern (Over-The-Counter Drugs, Prescription Drugs), Age Group, Indication - Forecast 2024-2030

Global Omega 3 Prescription Drugs Market Analysis & Forecast 2024-2034: Market By Drug; By Application; By Distribution Channel; and By Region

Organ Transplant Immunosuppressant Drugs - Global Strategic Business Report

About the Prescription Drugs Market